https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-95
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-30 / Cell. Mol. Immunol. 2015 Jan;12(1):87-952014-06-30 00:00:002019-02-15 08:52:07Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-09 / Int. Rev. Immunol. 2014 Oct;33(5):428-402014-06-09 00:00:002019-02-15 08:52:08Ovarian cancer biology and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-06-01 / J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3134)2014-06-01 00:00:002014-06-01 00:00:00Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-07 / J Ovarian Res 2014 May;7:48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-07 / J Ovarian Res 2014 May;7:482014-05-07 00:00:002019-02-15 08:52:06The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-11
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2014-05-02 / Expert Rev Clin Immunol 2014 Jun;10(6):705-112014-05-02 00:00:002021-11-15 13:30:54Wilms‘ tumor gene 1 immunotherapy in pelvic gynecological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-18 / Front Immunol 2013 Nov;4:382
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-18 / Front Immunol 2013 Nov;4:3822013-11-18 00:00:002020-02-05 10:32:56Dendritic cell vaccination, immune regulation, and clinical outcomes in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e27059
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-11-06 / Oncoimmunology 2013 Dec;2(12):e270592013-11-06 00:00:002021-11-15 13:33:23Dendritic cell-based immunotherapy in ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-09-01 / Anticancer Res. 2013 Sep;33(9):3855-92013-09-01 00:00:002021-11-15 14:43:00Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-07-09 / Clin. Cancer Res. 2013 Sep;19(17):4801-152013-07-09 00:00:002019-04-03 09:09:02A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-18 / J Transl Med 2013 Jun;11:149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-18 / J Transl Med 2013 Jun;11:1492013-06-18 00:00:002019-02-15 08:52:12A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
